AdvisorShares Pure Cannabis ETF (YOLO)

Key Updates

YOLO declined 3.70% to $2.60 since the April 7th report, extending the downtrend that erased the brief April 5th recovery. The ETF now trades at its lowest level in the reporting period, down 21.21% YTD and 30.67% over six months. Two significant sector developments emerged: Mary's Medicinals announced participation in a CMS cannabinoid therapy trial program representing potential federal legitimization, while Cambria liquidated its Cannabis ETF (TOKE), signaling continued investor exodus from the sector. The confluence of regulatory progress and competitive fund closures creates a complex risk-reward environment.

Current Trend

YOLO remains in a severe downtrend with the YTD decline of 21.21% accelerating from the six-month loss of 30.67%. The April 5th surge of 8.24% proved unsustainable, followed by consecutive declines of 2.17% and 3.70% that pushed the ETF to $2.60. The pattern of failed rallies persists, with each recovery attempt immediately reversed. Short-term momentum indicators show accelerating weakness, with the one-month decline of 10.34% representing the steepest compression. The $2.55 level tested on April 2nd has been breached, establishing $2.60 as the new support level with no clear resistance until the $2.76 level from April 5th. The technical structure indicates capitulation selling with no evidence of stabilization.

Investment Thesis

The core thesis for cannabis ETF exposure centers on federal rescheduling progress and state market maturation, offset by oversupply dynamics and regulatory uncertainty. The CMS cannabinoid therapy trial program represents a breakthrough in federal acceptance, establishing Medicare and Medicaid pathways for cannabinoid products up to 3mg THC through ACO REACH and Enhancing Oncology Model programs beginning in 2027. This institutional validation could catalyze broader acceptance. However, Tilray's aggressive diversification into craft beer, with cannabis representing only 31% of its $427 million revenue, signals that major operators are hedging against delayed federal legalization. The liquidation of competing ETF TOKE reduces sector capital allocation options, potentially consolidating flows into remaining vehicles like YOLO.

Thesis Status

The investment thesis shows contradictory signals that have deteriorated the risk-reward profile. The CMS trial program announcement represents the most significant federal legitimization development since rescheduling discussions began, validating cannabinoids as potential alternatives to opioids and synthetic pharmaceuticals within established healthcare models. Patient access through the LEAD model starting 2027 creates a defined timeline for institutional adoption. However, this positive development has failed to arrest YOLO's decline, with the ETF falling 3.70% since the announcement. The Cambria ETF liquidation confirms that institutional investors are abandoning dedicated cannabis exposure despite regulatory progress. The thesis remains intact fundamentally but faces severe timing risk, as evidenced by Tilray's diversification strategy in response to "delayed U.S. cannabis legalization." The gap between regulatory advancement and market response has widened substantially.

Key Drivers

Federal legitimization through the CMS cannabinoid therapy trial program establishes Medicare and Medicaid pathways for cannabinoid products, targeting outcomes evaluation as alternatives to traditional pharmaceuticals. The program operates through ACO REACH and Enhancing Oncology Model frameworks with patient access beginning 2027 through the LEAD model. Sector consolidation intensifies as Cambria liquidates TOKE, which represented less than 1% of its $4.1 billion AUM, signaling that even diversified asset managers are exiting dedicated cannabis vehicles. Product innovation continues with Curaleaf's Select Briq 2 launch across 13 states addressing the 58% of vape users seeking clogging solutions, and Smokiez Edibles' CBN expansion targeting 50-70 million Americans with chronic sleep disorders. Diversification strategies dominate as Tilray acquires BrewDog's U.S. assets, reducing cannabis to 31% of revenue amid federal legalization delays.

Technical Analysis

YOLO trades at $2.60, establishing a new multi-period low after breaching the $2.55 support tested on April 2nd. The ETF has declined in three of the last four sessions, erasing the April 5th recovery of 8.24% with subsequent losses totaling 5.87%. The downtrend exhibits accelerating momentum with the one-month decline of 10.34% exceeding the five-day loss of 1.14%, indicating intensifying selling pressure. Resistance levels are clearly defined at $2.76 (April 5th high) and $2.87 (April 2nd level), while support has collapsed with no technical floor established below current levels. The YTD decline of 21.21% and six-month loss of 30.67% reflect structural deterioration rather than temporary weakness. Volume patterns suggest capitulation with failed rallies immediately reversed, indicating lack of institutional accumulation. The technical structure offers no evidence of bottoming formation, with each bounce proving shorter and weaker than the previous attempt.

Bull Case

• Federal legitimization breakthrough: The CMS cannabinoid therapy trial program establishes Medicare and Medicaid pathways for cannabinoid products up to 3mg THC, representing unprecedented federal acceptance through established healthcare models including ACO REACH and Enhancing Oncology Model with patient access beginning 2027.
• Institutional healthcare validation: The CMS program positions cannabinoids as evaluated alternatives to opioids and synthetic prescription drugs within Accountable Care Organizations, creating data-driven pathways for broader pharmaceutical acceptance and reimbursement frameworks.
• Reduced competition for capital: The liquidation of Cambria Cannabis ETF (TOKE) eliminates a competing vehicle for dedicated cannabis exposure, potentially consolidating investor flows into remaining ETFs like YOLO as the sector rationalizes.
• Wellness market expansion: Smokiez Edibles' CBN expansion targets 50-70 million Americans with chronic sleep disorders according to CDC data, addressing massive wellness markets beyond recreational use with expansion planned across 10 additional states including California, New York, and Illinois.
• Product innovation momentum: Curaleaf's Select Briq 2 launch addresses 58% of cannabis vape users seeking clogging solutions with proprietary Flavor Protection Technology, rolling out across 13 states with over 60 strains, demonstrating continued investment in premium product development.

Bear Case

• Institutional abandonment despite regulatory progress: The Cambria ETF liquidation signals that institutional investors are exiting dedicated cannabis exposure even as federal programs advance, with TOKE's closure following comprehensive product lineup review by a firm managing $4.1 billion in assets.
• Major operators hedging against sector: Tilray's aggressive diversification into craft beer through BrewDog acquisitions reflects management's assessment that U.S. cannabis legalization remains delayed, with cannabis representing only 31% ($132 million) of $427 million total revenue as the company ranks 4th among U.S. craft brewers.
• Severe technical deterioration: YOLO's YTD decline of 21.21% and six-month loss of 30.67% demonstrate structural weakness, with the ETF establishing new lows at $2.60 and exhibiting failed rally patterns including the complete reversal of the April 5th 8.24% surge within three sessions.
• Delayed monetization timeline: The CMS trial program establishes patient access beginning in 2027 through the LEAD model, creating an extended timeline before institutional adoption translates to revenue, while evaluation of cannabinoids' impact on patient outcomes remains uncertain.
• Equity market stress for cannabis operators: Tilray's stock fell below $1 in 2025, briefly facing Nasdaq delisting risk, illustrating the severe valuation compression affecting cannabis operators and undermining the fundamental holdings within cannabis-focused ETFs like YOLO.